As part of our mission to improve medical care, Oregon Center for Clinical Investigations, Inc. is dedicated to the management and timely completion of clinical research trials. Sponsors can rely on OCCI, Inc. to efficiently complete clinical trials in a competent and professional manner.
20 Years of Clinical/Research Experience
Beal G. Essink, MD received a bachelor’s degree in premedical sciences in 1994 and a medical degree in 1996, both from the University of Nebraska Medical Center. He completed a psychiatry residency at the Oregon Health and Science University, where he was chief resident from 1999 to 2000. Dr. Essink is currently the lead principal investigator for OCCI, Inc.’s Portland location, in addition to acting as principal investigator/sub-investigator at the Salem location of OCCI, Inc. Since 2003, Dr. Essink has been an investigator for over 200 central nervous system and internal medicine clinical trials. Dr. Essink is a diplomate of the American Board of Psychiatry and Neurology in psychiatry and sleep medicine.
Drissana T. Tran, MD-Internal Medicine
24 Years of Clinical Experience
Drissana T. Tran, MD, obtained a bachelor’s degree in 1988 from the Robert D. Clark Honors College at the University of Oregon and a medical degree in 1992 from the Oregon Health Sciences University. She completed an internal medicine residency at Emanuel and Good Samaritan Hospitals in Portland, OR. In clinical practice since 1992, Dr. Tran has over 7 years of clinical research experience and has recently re-joined the OCCI, Inc. Salem location, where she is currently a clinical research investigator and rater for a variety of internal medicine and central nervous system studies. Dr. Tran is board-eligible in internal medicine.
Each OCCI, Inc. site is supported by a staff of highly trained and experienced site directors, research coordinators and assistants, PSG technicians, and administrative personnel. All OCCI, Inc. staff are committed to providing quality patient care to our communities and successfully completing each of our clinical trials.